<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199498</url>
  </required_header>
  <id_info>
    <org_study_id>R-04-399</org_study_id>
    <secondary_id>HSREB # 10880</secondary_id>
    <nct_id>NCT00199498</nct_id>
  </id_info>
  <brief_title>Right Apical Versus Septal Pacing Trial</brief_title>
  <acronym>RASP</acronym>
  <official_title>Right Apical Versus Septal Pacing Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether RV (right ventricular)septal pacing has any
      effect on LV ( left ventricular) function than RV apical pacing in patients who require
      ventricular pacing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare the effect of RV pacing site on LV systolic
      function as measured by LVEF (left ventricular ejection fraction).

      Secondary objectives of this trial include:

        1. to compare the effect of RVSeptal(RVS) versus RVApical(RVA)pacing on other indices of
           systolic and diastolic LV function

        2. to compare the rate of heart failure-related hospitalization between RVS versus RVA
           pacing

        3. to compare new-onset atrial fibrillation and stroke rates between RVS versus RVA pacing

        4. to assess the effect of RVA versus RVS pacing on quality of life and functional capacity

        5. to compare the rate of successful pacemaker lead implantation, complications and chronic
           electrical performance of RVS versus RVA pacing
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LV ejection fraction measured by radionuclide ventriculography (RVG).</measure>
    <time_frame>2 weeks, 24 months and 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular diastolic and systolic function indices 2-D echocardiogram/Doppler (ECHO/DOPP).</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal thromboembolic events including stroke.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalization or intravenous drug therapy in an outpatient heart failure clinic.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new-onset atrial fibrillation or progression to permanent atrial fibrillation.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms and quality of life scores (DUke Activity Status Index, short form (SF)-12 scores.</measure>
    <time_frame>2 weeks, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class using SAS survey, 6 minute hall walk distance.</measure>
    <time_frame>2 weeks, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lead-related complications such as lead dislodgement, myocardial perforation, lead integrity failure, high pacing threshold</measure>
    <time_frame>2 weeks, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total implant procedure and fluoroscopy time</measure>
    <time_frame>Implant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Heart Block</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Septal RV lead placement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient randomized to Septal RV lead placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apical RV lead placement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient randomized to Apical RV lead placement (current standard placement)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apical RV lead placement</intervention_name>
    <description>RV lead implanted ( according to randomization )at the apex</description>
    <arm_group_label>Apical RV lead placement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Septal RV lead placement</intervention_name>
    <description>RV lead is implanted (according to randomization), on septum</description>
    <arm_group_label>Septal RV lead placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. a)Fixed (third degree) AV block b) Atrial Fibrillation with average Ventricular rate
             on ECG &lt;/= 40bpm or mean heart rate on Holter monitor &lt;/= 60bpm c) Sinus node
             Dysfunction with PR interval &gt;/= 300msec d) Paroxysmal, persistent or permanent AF
             undergoing AV node , AV node/HIS ablation e) 2°AV Block with ≥3:1 block

          2. the subject is 18 years of age or older

          3. the subject has provided written consent -

        Exclusion Criteria:

          1. Pre-existing permanent cardiac pacemaker or ICD (defibrillator)

          2. Presence of Hypertrophic Obstructive Cardiomyopathy

          3. Recent cardiac surgery (&lt;/= 30 days)

          4. Recent myocardial infarction (&lt;/= 30 days)

          5. Presence of mechanical prosthetic tricuspid valve

          6. Patient inability or unwillingness to comply with study protocol and required study
             visit schedule

          7. Concomitant research study whose protocol would conflict or affect the outcome of this
             study

          8. Patient not expected to survive for the duration of the study follow-up due to
             co-morbid medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Yee, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Raymond Yee</investigator_full_name>
    <investigator_title>Dr.Raymond Yee MD FRCPC</investigator_title>
  </responsible_party>
  <keyword>Permanent Pacemaker Implantation- Lead Position</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Block</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

